New study finds genetic alterations in the VAC14 gene are associated with an increased risk of docetaxel-induced peripheral neuropathy in prostate cancer patients.
Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel.
Peripheral neuropathy is a common side effect of taxane treatment. Patients who suffer from this condition have damage to their peripheral nerves and experience weakness, numbness and pain usually in their hands or feet and occasionally in other areas of the body. This can limit the use of an otherwise effective cancer treatment.
In a study published online May 3 in the journal Clinical Cancer Research, researchers analyzed the DNA of men who had castrate-resistant metastatic prostate cancer and participated in a randomized phase 3 clinical trial that included docetaxel in the treatment regimen. Out of 623 prostate cancer patients from the study, 50 (8.1%) experienced debilitating peripheral neuropathy.
The researchers examined the patients' DNA for genetic variations called single nucleotide polymorphisms (SNPs) that were associated with docetaxel-induced peripheral neuropathy. They discovered that a variation in the VAC14 gene was highly associated with the incidence of docetaxel-induced peripheral neuropathy.
"The genetic variant of VAC14 identified in this study could be useful for understanding the mechanism of docetaxel-induced neuropathy and may be informative for avoiding docetaxel treatment in patients at elevated neuropathy risk," said Howard McLeod, Pharm.D., medical director of the DeBartolo Family Personalized Medicine Institute at Moffitt. "This also offers new drug development strategies to improve the outcomes for cancer patients."
The research was supported by grants from the National Institutes of Health (grants U01GM61390, U01GM61393, P30NR014129), ALLIANCE (CA31936 and CA33601), and ECOG-ACRIN (CA21115 and CA16116).
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy. Daniel L. Hertz, Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William K Kelly, Jai N Patel, Susan Halabi, Yoichi Furukawa, Heather E. Wheeler, Alexander Sibley, Cameron Lassiter, Lois S Weisman, Dorothy Watson, Stefanie D Krens, Flora Mulkey, Cynthia L Renn, Eric J Small, Philip G Febbo, Ivo Shterev, Deanna Kroetz, Paula N Friedman, John F Mahoney, Michael A. Carducci, Michael J Kelley, Yusuke Nakamura, Michiaki Kubo, Susan G Dorsey, M. Eileen Dolan4, Michael J. Morris, Mark J. Ratain, and Howard L McLeod. Clinical Cancer Research. DOI:10.1158/1078-0432.CCR-15-2823. Published online May 3, 2016.